These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 31449666)

  • 21. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
    Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.
    Garg A; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.
    Burvenich IJ; Farrugia W; Lee FT; Catimel B; Liu Z; Makris D; Cao D; O'Keefe GJ; Brechbiel MW; King D; Spirkoska V; Allan LC; Ramsland PA; Scott AM
    MAbs; 2016; 8(4):775-86. PubMed ID: 27030023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies.
    Wang W; Vlasak J; Li Y; Pristatsky P; Fang Y; Pittman T; Roman J; Wang Y; Prueksaritanont T; Ionescu R
    Mol Immunol; 2011 Mar; 48(6-7):860-6. PubMed ID: 21256596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a Pharmacokinetic Model Describing Neonatal Fc Receptor-Mediated Recycling of HL2351, a Novel Hybrid Fc-Fused Interleukin-1 Receptor Antagonist, to Optimize Dosage Regimen.
    Ngo L; Oh J; Kim A; Back HM; Kang WH; Chae JW; Yun HY; Lee H
    CPT Pharmacometrics Syst Pharmacol; 2020 Oct; 9(10):584-595. PubMed ID: 32945613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study.
    Zheng Y; Scheerens H; Davis JC; Deng R; Fischer SK; Woods C; Fielder PJ; Stefanich EG
    Clin Pharmacol Ther; 2011 Feb; 89(2):283-90. PubMed ID: 21191378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human FcRn Transgenic Mice for Pharmacokinetic Evaluation of Therapeutic Antibodies.
    Roopenian DC; Christianson GJ; Proetzel G; Sproule TJ
    Methods Mol Biol; 2016; 1438():103-14. PubMed ID: 27150086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions.
    Getman KE; Balthasar JP
    J Pharm Sci; 2005 Apr; 94(4):718-29. PubMed ID: 15682382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn.
    Chen Y; Balthasar JP
    AAPS J; 2012 Dec; 14(4):850-9. PubMed ID: 22956476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced elimination of IgG antibodies by engineering the variable region.
    Igawa T; Tsunoda H; Tachibana T; Maeda A; Mimoto F; Moriyama C; Nanami M; Sekimori Y; Nabuchi Y; Aso Y; Hattori K
    Protein Eng Des Sel; 2010 May; 23(5):385-92. PubMed ID: 20159773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study.
    Ling LE; Hillson JL; Tiessen RG; Bosje T; van Iersel MP; Nix DJ; Markowitz L; Cilfone NA; Duffner J; Streisand JB; Manning AM; Arroyo S
    Clin Pharmacol Ther; 2019 Apr; 105(4):1031-1039. PubMed ID: 30402880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantification of Neonatal Fc Receptor and Beta-2 Microglobulin in Human Liver Tissues by Ultraperformance Liquid Chromatography-Multiple Reaction Monitoring-based Targeted Quantitative Proteomics for Applications in Biotherapeutic Physiologically-based Pharmacokinetic Models.
    Qiu X; Wang MZ
    Drug Metab Dispos; 2020 Oct; 48(10):925-933. PubMed ID: 32723849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of FcRn binding assays to guide mAb development.
    Datta-Mannan A; Wroblewski VJ
    Drug Metab Dispos; 2014 Nov; 42(11):1867-72. PubMed ID: 25024401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular Neonatal Fc Receptor Recycling Efficiencies can Differentiate Target-Independent Clearance Mechanisms of Monoclonal Antibodies.
    Bryniarski MA; Tuhin MTH; Acker TM; Wakefield DL; Sethaputra PG; Cook KD; Soto M; Ponce M; Primack R; Jagarapu A; LaGory EL; Conner KP
    J Pharm Sci; 2024 Sep; 113(9):2879-2894. PubMed ID: 38906252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice.
    Richter WF; Christianson GJ; Frances N; Grimm HP; Proetzel G; Roopenian DC
    MAbs; 2018 Jul; 10(5):803-813. PubMed ID: 29621428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
    Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
    J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.
    Clemens PL; Yan X; Lokhorst HM; Lonial S; Losic N; Khan I; Jansson R; Ahmadi T; Lantz K; Zhou H; Puchalski T; Xu XS
    Clin Pharmacokinet; 2017 Aug; 56(8):915-924. PubMed ID: 27896689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of the interactions of rabbit neonatal Fc receptor (FcRn) with rabbit and human IgG isotypes.
    Szikora B; Hiripi L; Bender B; Kacskovics I; Iliás A
    PLoS One; 2017; 12(9):e0185662. PubMed ID: 28957416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Target-independent variable region mediated effects on antibody clearance can be FcRn independent.
    Kelly RL; Yu Y; Sun T; Caffry I; Lynaugh H; Brown M; Jain T; Xu Y; Wittrup KD
    MAbs; 2016 Oct; 8(7):1269-1275. PubMed ID: 27610650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys.
    Nnane IP; Han C; Jiao Q; Tam SH; Davis HM; Xu Z
    Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):13-21. PubMed ID: 28132416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.